GSK, Zymeworks expand partnership for bispecific antibody development
Category: #health  By Nikita Chaurasia  Date: 2019-05-18
  • share
  • Twitter
  • Facebook
  • LinkedIn

GSK, Zymeworks expand partnership for bispecific antibody development

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases

Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing and partnership agreement with Zymeworks for R&D and commercialization of bispecific antibodies for several types of diseases.

Apparently, under the extended agreement, GSK would be able to access to exclusive heavy-light chain pairing technology of Zymeworks as well as part of its branded Azymetric™ platform. The Azymetric platform from Zymeworks allows the development of bispecific drugs and multifunctional therapeutics while maintaining the features of naturally occurring human antibodies.

According to President and CEO of Zymeworks, Ali Tehrani, Ph.D., as part of this extended agreement GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs for the treatment of communicable diseases. It also highlights the efficacy of the company’s platform beyond traditional indications such as inflammatory disease and oncology.

Sources familiar with the matter mentioned that under the updated terms of the extended agreement, GSK will have the option to commercialize and develop bispecific drugs across different disease areas and Zymeworks would be eligible for receiving increased preclinical, research & development and commercial milestone payments.

Reportedly, once all six programs are commercialized and developed then the new potential value of the partnership would be around US$1.1 billion.  In addition, Zymeworks is entitled to receive augmented tiered royalties on global sales.

The Azymetric platform seemingly allows monospecific antibodies to convert into bispecific antibodies, providing the antibodies the capability to concurrently bind two different targets. Azymetric bispecific technology allows the development of multifunctional therapeutics that can restrict various signaling pathways, increase tumor-specific targeting, recruit immune cells to tumors, and enhance receptor clustering degradation.

These characteristics are proposed to improve efficacy while reducing the potential for drug resistance and toxicities, sources added. The Azymetric bispecifics have been engineered for retaining the required drug-like abilities of naturally occurring antibodies, including high stability, long half-life, and low immunogenicity.

 

Source Credit: https://www.businesswire.com/news/home/20190516005061/en/Zymeworks-GSK-Expand-2016-Azymetric%E2%84%A2-Bispecific-Agreement

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

WHO launches health worker “Florence” with digital brain
WHO launches health worker “Florence” with digital brain
By Nikita Chaurasia

In a recent turn of events, World Health Organization (WHO) has reportedly introduced an AI-based health worker called Florence to better manage myths related to coronavirus as well as smoking. Sources with relevant information stated that the techno...

Rolls-Royce ends the salary pension scheme earlier than expected
Rolls-Royce ends the salary pension scheme earlier than expected
By Nikita Chaurasia

Reportedly, Rolls-Royce, a subsidiary of German group BMW, is planning to close its final salary pension scheme 4 years earlier to ease up pressure mounted by the grounded aircrafts. If this initiative gets a green signal from the trustees and pensi...

Scientists say COVID-19 is airborne, ask WHO to revise recommendations
Scientists say COVID-19 is airborne, ask WHO to revise recommendations
By Nikita Chaurasia

Numerous scientists across the globe have reportedly sent an open letter to WHO (World Health Organization) seeking the health agency to revise recommendations regarding the novel coronavirus. As per credible reports, around 239 scientists from 32 c...